FDA Approves Rylaze for Childhood ALL - Cancer Currents Blog National Cancer Institute sent this bulletin at 07/30/2021 10:34 AM EDT The latest from the NCI Cancer Currents blog Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL 07/29/2021 FDA has approved a new form of asparaginase called Rylaze. The drug was developed to help alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia.
